middle.news
Zelira Secures US$681K Funding Boost for HOPE® Autism FDA Trials
6:47pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Zelira Secures US$681K Funding Boost for HOPE® Autism FDA Trials
6:47pm on Sunday 1st of June, 2025 AEST
Key Points
Fourth funding tranche of US$681,000 secured for HOPE® FDA trials
Total HOPE® SPV funding now US$3.25 million
FDA Phase 1 trial targeting irritability in Phelan McDermid Syndrome with ASD
Zenivol® capsule formulation development on track for early 2025 completion
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE